Table 1.
Population and tumor characteristics
| Patients, n | 86 |
| Median age (range), years | 51 (27–91) |
| Body mass index, mean (range) | 27.4 (18.4–47.4) |
| <25, n (%) | 15 (16.6) |
| 25–30, n (%) | 62 (68.8) |
| >30, n (%) | 13 (14.4) |
| Smoking status, n (%) | |
| Yes/No | 12 (13.9)/74 (76.1) |
| Density of breast tissue, n (%) | |
| 1 | 5 (5.8) |
| 2 | 31 (36) |
| 3 | 47 (54.6) |
| 4 | 3 (3.4) |
| Cup size, n (%) | |
| B | 20 (23.2) |
| C | 41 (47.6) |
| ≥D | 25 (29.2) |
| Tumor focality, n (%) | |
| UF (>50 mm) | 31 (36) |
| MFMC | 55 (64) |
| Tumor size, median (range), mm | |
| UF tumor | |
| Imaging | 58 (51–100) |
| Final pathology | 51 (50–60) |
| MFMC tumor | |
| Span of tumor | 65 (53 95) |
| Largest tumor size | 30 (22–60) |
| Location, n (%) | |
| Outer quadrant | 50 (58.1) |
| Upper | 40 (46.5) |
| Lower | 10 (11.6) |
| Inner quadrant | 15 (17.4) |
| Upper | 10 (11.6) |
| Lower | 5 (5.8) |
| Central | 10 (11.6) |
| Other | 11 (12.7) |
| Histological type, n (%) | |
| Invasive | 72 (83.6) |
| Ductal | 56 (65.1) |
| Lobular | 10 (11.6) |
| Mixt | 6 (6.9) |
| Ductal carcinoma in situ | 2 (2.3) |
| Other | 12 (13.9) |
| Stage, n (%) | |
| 0 | 2 (2.3) |
| IIA | 28 (32.5) |
| IIB | 42 (48.8) |
| IIIA | 14 (16.2) |
| Grade, n (%) | |
| 1 | 11 (11.6) |
| 2 | 33 (38.3) |
| 3 | 42 (48.3) |
| Receptor status, n (%) | |
| ER+ | 71 (82.5) |
| PR+ | 67 (77.9) |
| HER2+ | 17 (19.7) |
| TNBC | 8 (9.3) |
| Pathological nodal status, n (%) | |
| pN0 | 31 (36.1) |
| pN1 | 37 (43.1) |
| pN2 | 12 (13.9) |
| pN3 | 6 (6.9) |
| Systemic therapy, n (%) | |
| Neoadjuvant chemotherapy | 35 (40.7) |
| Adjuvant chemotherapy | 47 (54.6) |
| Endocrine therapy | 75 (87.2) |
| Radiation therapy, n (%) | 86 (100) |
UF, unifocal; MFMC, multifocal-multicentric; mm, millimeter; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer.